Sun Pharmaceutical Industries Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹1137.1
- Today's High:
- ₹1154
- Open Price:
- ₹1144.95
- 52W Low:
- ₹847.4628
- 52W High:
- ₹1169.9
- Prev. Close:
- ₹1137.1
- Volume:
- 207256
Company Statistics
- Market Cap.:
- ₹2,670.81 billion
- Book Value:
- 233.379
- Revenue TTM:
- ₹450.65 billion
- Operating Margin TTM:
- 21.82%
- Gross Profit TTM:
- ₹332.24 billion
- Profit Margin:
- 18.72%
- Return on Assets TTM:
- 7.73%
- Return on Equity TTM:
- 15.43%
Company Profile
Sun Pharmaceutical Industries Limited had its IPO on under the ticker symbol SUNPHARMA.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Sun Pharmaceutical Industries Limited has a staff strength of 41,000 employees.
Stock update
Shares of Sun Pharmaceutical Industries Limited opened at ₹1144.95 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹1137.1 - ₹1154, and closed at ₹1145.15.
This is a +0.71% increase from the previous day's closing price.
A total volume of 207,256 shares were traded at the close of the day’s session.
In the last one week, shares of Sun Pharmaceutical Industries Limited have increased by +3.29%.
Sun Pharmaceutical Industries Limited's Key Ratios
Sun Pharmaceutical Industries Limited has a market cap of ₹2,670.81 billion, indicating a price to book ratio of 4.4842 and a price to sales ratio of 5.8518.
In the last 12-months Sun Pharmaceutical Industries Limited’s revenue was ₹450.65 billion with a gross profit of ₹332.24 billion and an EBITDA of ₹122.65 billion. The EBITDA ratio measures Sun Pharmaceutical Industries Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sun Pharmaceutical Industries Limited’s operating margin was 21.82% while its return on assets stood at 7.73% with a return of equity of 15.43%.
In Q2, Sun Pharmaceutical Industries Limited’s quarterly earnings growth was a negative -2.3% while revenue growth was a positive 11%.
Sun Pharmaceutical Industries Limited’s PE and PEG Ratio
- Forward PE
- 24.6305
- Trailing PE
- 31.7046
- PEG
Its diluted EPS in the last 12-months stands at ₹35.11 per share while it has a forward price to earnings multiple of 24.6305 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sun Pharmaceutical Industries Limited’s profitability.
Sun Pharmaceutical Industries Limited stock is trading at a EV to sales ratio of 5.6084 and a EV to EBITDA ratio of 30.4597. Its price to sales ratio in the trailing 12-months stood at 5.8518.
Sun Pharmaceutical Industries Limited stock pays annual dividends of ₹0 per share, indicating a yield of 1.04% and a payout ratio of 31.44%.
Balance sheet and cash flow metrics
- Total Assets
- ₹807.44 billion
- Total Liabilities
- ₹199.06 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 31.44%
Sun Pharmaceutical Industries Limited ended 2024 with ₹807.44 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹807.44 billion while shareholder equity stood at ₹559.95 billion.
Sun Pharmaceutical Industries Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹199.06 billion in other current liabilities, 2399300000.00 in common stock, ₹557.55 billion in retained earnings and ₹87.13 billion in goodwill. Its cash balance stood at ₹46.24 billion and cash and short-term investments were ₹159.07 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹5.60 billion.
Sun Pharmaceutical Industries Limited’s total current assets stands at ₹398.62 billion while long-term investments were ₹0 and short-term investments were ₹101.37 billion. Its net receivables were ₹114.39 billion compared to accounts payable of ₹56.82 billion and inventory worth ₹105.13 billion.
In 2024, Sun Pharmaceutical Industries Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Sun Pharmaceutical Industries Limited paid ₹0.31 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹1145.15
- 52-Week High
- ₹1169.9
- 52-Week Low
- ₹847.4628
- Analyst Target Price
- ₹
Sun Pharmaceutical Industries Limited stock is currently trading at ₹1145.15 per share. It touched a 52-week high of ₹1169.9 and a 52-week low of ₹1169.9. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹1111.42 and 200-day moving average was ₹1018.3 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5450.8% of the company’s stock are held by insiders while 2537.4% are held by institutions.
Frequently Asked Questions About Sun Pharmaceutical Industries Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and anti retro viral medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.